Rivastigmine in the treatment of Sleep REM Behaviour Disorder (RBD) and Hallucinations in Parkinsonism: a Clinical and Polysomnographic study? - ND

• Conditions: PARKINSONISM; MedDRA version: 9.1Level: SOCClassification code 10029205; MedDRA version: 9.1Level: HLTClassification code 10034005

• Registration Number: EUCTR2009-012071-10-IT
• Lead Sponsor: POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2009-05-29
• Last Update Posted: 19 March 2012

Recruitment & Eligibility

• Status: ot Recruiting
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

- Clinical and Polysomnographic diagnosis of RBD (REM Sleep Behavior Disorders) based on the ICD (International Classification of Sleep Disorders; 2005) criteria (Manual of the?American Academy of Sleep Medicine?) -Both Sex, age< 70 years -Written Consensus
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range

Exclusion Criteria

- MMSE<24 -Side intolerable effects referred to Rivastigmine -Gastric ulcer -Epileptic seizures -Urinary Occlusion -Sinus-node disease -Cardiac Conduction Defects (sino-atrial block; atrioventricular block) -Bronchopneumopathy Chronic obstructive (BPCO)

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified